Chiesi Group, a research-oriented international biopharmaceutical group headquartered in Parma, Italy, recorded a turnover of €2.7 billion in 2022, an increase of 13.6% from 2021.

The company reported that its gross operating profit (EBITDA) grew by 7% and it has a solid positive net financial position of €1,390 million, €342 million more than previous year.

In a statement, the company said that the biggest share of turnover (70%) comes from treatments for respiratory disease, followed by products for rare and ultra-rare diseases, which registered record revenues of €332 million in 2022, growing 18% from 2021.

Giuseppe Accogli, the Chiesi Group’s new CEO, said: “This excellent performance is concrete evidence of the Group’s work in creating shared value for people, the community, and the environment. It has been possible thanks to the commitment of all our people globally. A commitment that I share, together with the Chiesi family, and that will drive us into the next stages of international growth.”

In addition, R&D investments increased to reach 21.4% of turnover. Chiesi registered 42 new patents at the European Patent Office (EPO) in 2022, ranking as the first Italian pharmaceutical company in terms of applications.

Research growth is mainly driven by partnerships and collaborations (Allinaire Therapeutics, Aptar Digital health, Kaia Health) and acquisitions (Amryt). In 2022, Chiesi also started building its Parma Biotech Center of Excellence, the new hub for the development of biological products, made possible by a €85 million investment.

In July 2022, Chiesi – a Benefit Corporation in Italy (Società Benefit), the United States and France (Société à Mission) – achieved B Corp recertification by international non-profit organization B Lab. The milestone, according to the company, represents the starting point of a new, three-year improvement plan, aiming for a recertification in 2025.

In 2023, the company said that it aims to grow further, and expects to reach and exceed its budget targets.